AI Discrimination of Adenocarcinoma vs. Squamous Carcinoma in Detecting NSCLC Non-Invasively from Sputum Using Cell-CT Single-Cell Analysis in 3D

Background

LuCED® Test Based on Cell-CT Analysis:

The Cell-CT platform analyzes cells in true 3D, measuring >900 morphology biomarkers in each single cell with isometric 200nm resolution. The image below is of a columnar cell from the lung epithelium. LuCED AI identifies cells with abnormal features that are then cytologically diagnosed using VisionGate’s digital pathology workstation, CellGazer . Cells that are in neoplastic categories, from atypia to cancer, trigger a LuCED report of abnormality. In published work, sensitivity to stage 1 lung cancer is 94% and specificity is 97%1. Sensitivity is selectable, as it is governed by the number of normal bronchial epithelial cells (BECs) that are enumerated following the SAT curve shown in the full PDF.